Who Paid My Doc
A Phase I/II Observer-Blind, Randomized, Placebo Controlled, Multi-Cen
Research payments
$1,939,393
Through program year 2024, $1,939,393 in research payments was reported against A Phase I/II Observer-Blind, Randomized, Placebo Controlled, Multi-Cen, across 158 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $2,290 | 3 |
| 2023 | Research | $673,164 | 66 |
| 2022 | Research | $1,145,515 | 76 |
| 2021 | Research | $118,423 | 13 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
7 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Jon Finley Atlanta, GA Named on 27 payments
- Marian Shaw Boise, ID Named on 26 payments
- Barbara Rizzardi West Jordan, UT Named on 22 payments
- Sylvia Shoffner Cary, NC Named on 19 payments
- Vicki Miller Tomball, TX Named on 14 payments
- Margaret Rhee Beachwood, OH Named on 8 payments
- Kevin Cannon Wilmington, NC Named on 6 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.